Open Access. Powered by Scholars. Published by Universities.®
Busulfan;; Bone marrow transplant;; Elderly;; Pharmacokinetics;; BONE-MARROW-TRANSPLANTATION;; HIGH-DOSE BUSULFAN;; DAILY IV BUSULFAN;; INTRAVENOUS BUSULFAN;; BODY-WEIGHT;; VENOOCCLUSIVE DISEASE;; CONDITIONING;; THERAPY;; SYSTEMIC EXPOSURE;; OLDER PATIENTS;; CHILDREN;; Oncology;; Pharmacology & Pharmacy
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Effect Of Age On The Pharmacokinetics Of Busulfan In Patients Undergoing Hematopoietic Cell Transplantation; An Alliance Study (Calgb 10503, 19808, And 100103), J. H. Beumer, K. Owzar, L. D. Lewis, C. Jiang, J. L. Holleran, S. M. Christner, W. Blum, S. Devine, J. E. Kolitz, M. J. Egorin, +5 Additional Authors
Effect Of Age On The Pharmacokinetics Of Busulfan In Patients Undergoing Hematopoietic Cell Transplantation; An Alliance Study (Calgb 10503, 19808, And 100103), J. H. Beumer, K. Owzar, L. D. Lewis, C. Jiang, J. L. Holleran, S. M. Christner, W. Blum, S. Devine, J. E. Kolitz, M. J. Egorin, +5 Additional Authors
Journal Articles
Older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome have often been excluded from myeloablative-conditioning regimens containing busulfan because of non-disease-related morbidity and mortality. We hypothesized that busulfan clearance (BuCL) in older patients (> 60 years) would be reduced compared to that in younger patients, potentially explaining observed differences in busulfan tolerability. AML patients in three CALGB hematopoietic cell transplantation studies were treated with a conditioning regimen using IV busulfan, dosed at 0.8 mg/kg. Plasma busulfan concentrations were determined by LC-MS and analyzed by non-compartmental methods. BuCL was normalized to actual (ABW), ideal (IBW), or corrected (CBW) body weight …